Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cue Biopharma Inc (NQ: CUE ) 0.7033 +0.0073 (+1.05%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 199,632 Open 0.7196 Bid (Size) 0.6900 (2) Ask (Size) 0.7000 (4) Prev. Close 0.6960 Today's Range 0.6810 - 0.7500 52wk Range 0.6810 - 3.950 Shares Outstanding 44,959,548 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements Today 16:05 EDT From Cue Biopharma, Inc. Via GlobeNewswire Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting June 04, 2024 From Cue Biopharma, Inc. Via GlobeNewswire Performance YTD -74.70% -74.70% 1 Month -51.33% -51.33% 3 Month -50.12% -50.12% 6 Month -73.95% -73.95% 1 Year -81.44% -81.44% More News Read More Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024 June 03, 2024 From Cue Biopharma, Inc. Via GlobeNewswire Forecasting The Future: 4 Analyst Projections For Cue Biopharma April 09, 2024 Via Benzinga Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain March 13, 2024 Via Investor Brand Network Medical Moonshots: 3 Biotech Stocks Set to Skyrocket May 30, 2024 Via InvestorPlace CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights May 09, 2024 From Cue Biopharma, Inc. Via GlobeNewswire Cue Biopharma to Present at the 20th Annual PEGS Boston Summit May 08, 2024 From Cue Biopharma, Inc. Via GlobeNewswire Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference May 07, 2024 From Cue Biopharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's After-Market Session May 02, 2024 Via Benzinga Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From Cue Biopharma, Inc. Via GlobeNewswire Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights April 08, 2024 From Cue Biopharma, Inc. Via GlobeNewswire CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023 April 02, 2024 Via InvestorPlace Cue Biopharma to Host Business Update Call and Webcast April 02, 2024 From Cue Biopharma, Inc. Via GlobeNewswire Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session March 13, 2024 Via Benzinga Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium February 29, 2024 From Cue Biopharma, Inc. Via GlobeNewswire Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 06, 2024 From Cue Biopharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session January 01, 2024 Via Benzinga CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023 December 14, 2023 Via InvestorPlace Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit November 22, 2023 From Cue Biopharma, Inc. Via GlobeNewswire Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights November 09, 2023 From Cue Biopharma, Inc. Via GlobeNewswire Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November November 07, 2023 From Cue Biopharma, Inc. Via GlobeNewswire Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023 November 03, 2023 From Cue Biopharma, Inc. Via GlobeNewswire Cue Biopharma to Host Business Update Call and Webcast November 02, 2023 From Cue Biopharma, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
